ADC Therapeutics (ADCT) Notes Payables (2022 - 2023)
ADC Therapeutics (ADCT) posted quarterly Notes Payables of $14.3 million for Q3 2023, up 14.63% year-on-year from $12.5 million in Q3 2022, and up 3.09% on a QoQ basis from $13.9 million in Q2 2023.
ADC Therapeutics (ADCT) Notes Payables (2022 - 2023) Analysis & Trends
ADC Therapeutics (ADCT) has reported Notes Payables for 2 consecutive years, with $14.3 million the latest figure, recorded in Q3 2023.
- Quarterly Notes Payables rose 14.63% year-over-year to $14.3 million in Q3 2023, while the trailing twelve-month figure through Sep 2023 was $14.3 million (up 14.63% YoY) and the FY2022 annual result came in at $12.5 million, changed N/A from the prior year.
- Notes Payables grew to $14.3 million in Q3 2023 per ADCT's latest filing, from $13.9 million in the prior quarter.
- Over the last five years, Notes Payables for ADCT reached as high as $14.3 million in Q3 2023 and fell as low as $12.5 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | ADC Therapeutics | 189.60 Mn | -41.41 Mn | 17.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 14.33 Mn |
| Jun 30, 2023 | 13.90 Mn |
| Mar 31, 2023 | 13.53 Mn |
| Dec 31, 2022 | 12.47 Mn |
| Sep 30, 2022 | 12.50 Mn |